Methylation at many gene promoters has been reported to have independent prognostic value in breast cancer including HOXA11 [65], ESR1 and PITX2 [66], HOXD13 [67] CDH22 [68] BRCA1 and RASSF1 [69, 70]. This evidence concerns the gene CDH22 and breast cancer.